Enhabit, Inc. (EHAB) Q3 2025 Earnings Call Transcript

Enhabit, Inc. (EHAB) delivered strong Q3 2025 results, with consolidated net revenue up 3.9% year-over-year to $263.6 million and adjusted EBITDA increasing 10.2% to $27 million, expanding margins to 10.2%. The Home Health segment achieved 3.6% admission growth and 3.7% census increase, successfully renegotiating national payer contracts for rate increases and piloting a visit per episode management program to mitigate future rate disruptions. Hospice demonstrated robust performance with 12.6% year-over-year census growth, driving a 20% revenue increase to $63.1 million and a 72% surge in adjusted EBITDA. The company significantly improved its financial health, reducing net debt to adjusted EBITDA leverage to 3.9x, and raised its full-year 2025 guidance for revenue, adjusted EBITDA, and adjusted free cash flow, while actively preparing for potential impacts from the proposed 2026 CMS home health rule.

Analysis

Enhabit, Inc. (EHAB) reported strong Q3 2025 results, with consolidated net revenue up 3.9% year-over-year to $263.6 million and adjusted EBITDA increasing 10.2% to $27 million. The company significantly improved its financial health, reducing net debt to adjusted EBITDA leverage to 3.9x from 5.4x in Q4 2023, supported by robust adjusted free cash flow.

The Hospice segment demonstrated robust performance, with 12.6% year-over-year census growth driving a 20% revenue increase and a 72% surge in adjusted EBITDA, bolstered by de novo strategy and increased sales team. Home Health admissions and census also grew despite early-quarter payer disruption.

Enhabit successfully renegotiated a national payer contract for a low double-digit rate increase, recovering census quickly. A visits per episode management pilot showed promising early results in reducing visits, complemented by sequential reductions in home office G&A. These efforts optimize cost structure and mitigate potential CMS rate headwinds.

Management raised its full-year 2025 guidance for revenue, adjusted EBITDA, and adjusted free cash flow, reflecting confidence in strategic execution. Despite potential pricing headwinds from the proposed 2026 CMS home health rule, Enhabit is actively deploying mitigation strategies, underscoring its ability to manage challenges and grow market share.

Key Decisions for Investors

• Investors should monitor Enhabit's ongoing success in payer contract renegotiations and the effectiveness of its visits per episode management pilot, which are crucial for mitigating future revenue pressures and optimizing cost structure.
• Evaluate the ultimate impact of the 2026 CMS home health final rule on the Home Health segment's profitability and the efficacy of Enhabit's stated mitigation strategies once more details are available.
• Consider the robust growth and margin expansion in the Hospice segment as a key driver of overall company performance and balance sheet improvement, providing diversification against Home Health segment risks.